Arrowhead shares sink with news of Novartis RNAi closure; Nordic Capital leads bidders for nicotine patch maker;

> Shares of Arrowhead ($ARWR) dropped over 8% with news that Novartis would be closing a large portion of its RNAi research arm in Boston, according to Street Register. Brief

> Swedish Nordic Capital is said to be a leading bidder for LTS Lohmann Therapie-Systeme, a German nicotine patch maker, according to a report in Bloomberg BusinessWeek. Story

> Moberg Pharma inked a deal with Oracain II Aps for global rights to its oral formulation of bupivacaine to treat pain in the oral cavity. Release

> IntelGenx ($IGXT) snagged a patent for its AdVersa mucoadhesive drug delivery technology. More

Suggested Articles

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.